Printer Friendly

SCIMED RECEIVES FDA APPROVAL TO MARKET DISPATCH CORONARY INFUSION CATHETER

 MINNEAPOLIS, Jan. 12 /PRNewswire/ -- SCIMED Life Systems, Inc. (NASDAQ-NMS: SMLS) announced today that it has received FDA approval to market its Dispatch(TM) coronary infusion catheter.
 The Dispatch is a non-dilatation, over-the-wire device designed for localized delivery of solutions directly to a specific portion of an artery wall. It is intended for coronary and general endovascular use and may be used in conjunction with angioplasty. The launch date for the product is undetermined. Early stage human clinical evaluations are under way in one leading European cardiovascular research center to help gain insights into appropriate future studies.
 Dale A. Spencer, president and chief executive officer, commented, "The Dispatch is SCIMED's first 'new technology' product to receive approval by the FDA. We are investing in the development of new technology products, which are new catheter-based tools to diagnose and treat cardiovascular disease, with an ongoing aim to improve upon clinical results and/or procedure cost-effectiveness."
 SCIMED Life Systems, Inc. develops, manufactures and markets disposable medical devices, principally coronary and peripheral angioplasty products, for non-surgical treatment of cardiovascular disease. SCIMED's shares are traded on the NASDAQ National Market System under the symbol SMLS.
 -0- 1/12/94
 /CONTACT: Karen J. Kelsey, director, Investor and Public Relations of SCIMED, 612-494-2329/
 (SMLS)


CO: SCIMED Life Systems, Inc. ST: Minnesota IN: MTC SU:

AL -- MN006 -- 1285 01/12/94 08:59 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1994
Words:226
Previous Article:J.D. POWER AND ASSOCIATES: THE POWER INFORMATION NETWORK; ADP DEALER SERVICES JOINS STRATEGIC ALLIANCE
Next Article:SUMMIT RECEIVES FDA APPROVAL TO CONDUCT CLINICAL TRIALS FOR TOPICAL PHARMACEUTICALS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters